Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients

NCT05735197 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Chronic Kidney Diseases
Bone Diseases, Metabolic

Interventions

DRUG: Dapagliflozin 10mg Tab
DRUG: Placebo

Sponsor

Mansoura University